{
  "docId": "019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "docSlug": "0f1a880702ed9ddf7f6316bb24fc6717",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 36,
  "pageCount": 37,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a combination of clinical timeline, patient history, and immunological data (ELISPOT) to correlate T-cell response with clinical outcome.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-d25f-763f-9eab-9ec8cb3a6b5e/36",
  "deckHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "deckJsonHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e.json",
  "deckAnchorHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.8,
        "w": 0.31,
        "x": 0.04,
        "y": 0.0018
      },
      "kind": "callout",
      "text": "Key Takeaways: Off-the-Shelf Personalized Medicine: Single Agent generates Individualized Results",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ae3acfb-faef-4e71-85dc-80cb8a88f0c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.37,
        "x": 0.61,
        "y": 0.12
      },
      "kind": "chart",
      "text": "IFN-gamma secreting cells / 100,000 PBMCs at Baseline, Week 6, and Week 30",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "079bd6e3-42e7-4e4b-8a9e-fe313da54ab2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.46,
        "x": 0.52,
        "y": 0.0052
      },
      "kind": "chart",
      "text": "SLD of target lesions over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fde3cd5-7010-456e-9fb1-0460c03ee621",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.17,
        "x": 0.35,
        "y": 0.0052
      },
      "kind": "diagram",
      "text": "Clinical timeline: Last Chemotherapy -> Progressive disease -> GL-ONC1 Tx -> Partial response -> Stable disease",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3c6b3a9-f28d-4988-91c1-d66e887602f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.29,
        "x": 0.05,
        "y": 0.0045
      },
      "kind": "list",
      "text": "Olvi-Vec induces favorable & long-lasting Tumor-specific T-cell Response (TSTcR) by ELISPOT analysis in heavily treated patient w/ 9 prior regimens of chemo; no Tumor-specific T-cell response at baseline. Documented OR from Olvi-Vec treatment after failure of last chemotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e5403dd-dbb9-4bd1-a710-a5469b48a006",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Long-lasting, Tumor-specific T cell response corresponds to tumor reduction",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "816d7a11-f1b2-4f55-9f90-1cd84f365d9e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Aha! Moment",
      "slug": "aha-moment",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "6ab93d7b-70f4-428b-aa0c-253e38e755c8",
      "evidence": "Long-lasting, Tumor-specific T cell response corresponds to tumor reduction",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "0c0154e9-9981-4761-ab1d-084af1322a1e",
      "evidence": "The slide contrasts the patient's state before and after Olvi-Vec treatment to demonstrate efficacy.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}